A Phase Ib Study of The Safety and Pharmacology of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 11 Apr 2018
At a glance
- Drugs Atezolizumab (Primary) ; Emactuzumab; Obinutuzumab
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors Roche
- 03 Apr 2018 Status changed to withdrawn prior to enrolment.
- 14 Mar 2018 Planned initiation date changed from 31 Jan 2018 to 14 Mar 2018.
- 31 Jan 2018 Status changed from not yet recruiting to recruiting.